WoS SCIE Q1CAS 2区Hybrid

Molecular Therapy-Oncolytics

Abbreviation (ISO):MOL THER-ONCOLYTICS

Country: United States•WoS SCIE Quartile: Q1•Identifier (ISSN):2372-7705(Print)•Articles / Year: 179

Clarivate Impact Factor (IF 2024)Q1

N/A

Leading citation impact metric from Clarivate Journal Citation Reports

H-Index (2021)

12 papers with at least that number of citations each

WoS: SCIE / JCRQ1

Self-Citation RateN/A

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

179articles/year

89.58% Gold OA•84.72% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

1.50pts

Latest Max Score

Estimated (Dec 26)

Scoring Basis: WoS Q2

HĐGSNN Score History

By article publication year

Year	Max Score	Evaluation Details	Source
2025	1.50đ	WoS Q2	🔵 Computed
2024	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 5.3)	🔵 Computed
2023	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 5.7)	🔵 Computed
2022	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 6.311)	🔵 Computed
2021	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 7.2)	🔵 Computed
2020	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 4.115)	🔵 Computed
2019	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 5.71)	🔵 Computed
2018	1.75đ	WoS Q2 có IF ≥ 2.0(IF: 3.69)	🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.

Topics Covered (Recognized by AI)

Biology99.4%Genetics98.7%Medicine98.3%Internal medicine93.1%Cancer research91.7%Cancer86%Chemistry85.4%Biochemistry84.6%Immunology65.9%Gene58.6%Immune system56.4%Tumor cells39.1%Virology36.7%Virus35.1%Oncolytic virus33.5%Cell biology32.1%Pathology27.8%Cancer cell27.1%Apoptosis26.6%In vitro26.1%Cell culture25%Immunotherapy24.7%Cell21.5%

Primary Research Areas

Medicine Oncology

Official Website NLM PubMed Catalog Submission Portal

SCImago & Scopus Journal Intelligence

Not indexed in SCImago / Scopus database

This journal is currently not indexed in Scopus or is an academic publication indexed exclusively in Web of Science (WoS).

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

2区 (Zone 2)Medicine

Minor Category (Specific Field):

3区MEDICINE, RESEARCH & EXPERIMENTAL

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed

Updating

Average time to first editorial decision

Online Publication Speed

Updating

Time from acceptance to online publication

Official Acceptance Rate

Updating

Manuscript acceptance rate confirmed by the publisher

Open Access Model

Hybrid

OA publishing option or traditional subscription

Publisher

Cell Press

Publication Language

English

Frequency

Periodic

Editorial Address

50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, USA, MA, 02139

Indexing & Databases

SCIEScopusDOAJPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR

No WoS category details available for this journal.

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

11 year

Year	Impact Factor	Articles / Year	Total Citations
2024	5.3	—	—
2023	5.7	93	1,137
2022	6.311	140	3,605
2021	7.2	189	5,966
2020	4.115	170	5,599
2019	5.71	83	3,776
2018	3.69	41	2,047
2017	—	32	1,320
2016	—	44	3,464
2015	—	18	595
2014	—	10	229